EN
 
EN

Mylan Worldwide

Close

Please select one of our websites from the list below.

  1. Europe

    1. Austria
      1. Deutsch
    2. Belgium
      1. Français
      2. Nederlands
    3. Czech Republic
      1. Čeština
    4. Denmark
      1. Dansk
    5. Finland
      1. Suomi
    6. France
      1. Français
    7. Germany
      1. Deutsch
    8. Greece
      1. Ελληνικά
    9. Hungary
      1. Magyar
    10. Ireland
      1. English
    11. Italy
      1. Italiano
    12. Netherlands
      1. Nederlands
    13. Norway
      1. Norsk
    14. Poland
      1. Polski
    15. Portugal
      1. Português
    16. Slovakia
      1. Slovenský
    17. Slovenia
    18. Spain
      1. Español
    19. Sweden
      1. Svensk
    20. Switzerland
      1. Deutsch
      2. English
    21. United Kingdom
      1. English
  2. Africa

    1. South Africa
      1. English
  3. Americas

    1. Brazil
      1. Português brasileiro
    2. Canada
      1. English
      2. Français
    3. United States
      1. English
  4. Asia

    1. India
      1. English
    2. Japan
      1. 日本語
  5. Pacific

    1. Australia
      1. English
    2. New Zealand
      1. English

Mylan is also proud to do business in these locations.

  1. Morocco
  2. Luxembourg
  3. Slovenia
  1. China
  2. Singapore
  3. Taiwan
Jan 1, 2014

Answers for an Epidemic

Answers for an Epidemic

See how an innovative, heat-stable antiretroviral (ARV) is changing HIV/AIDS treatment.

In developing countries where electricity is unpredictable, refrigeration tends to be scarce. HIV/AIDS, on the other hand, may be all too common. For the millions living with HIV/AIDS in places such as sub-Saharan Africa, a lack of refrigeration once meant a lack of access to antiretroviral medicines.

This is because one of the three different medicines required for one important HIV/AIDS treatment regimen breaks down if not refrigerated. The question we asked was: “Can we make an affordable, heat-stable version of this medicine accessible in sufficient quantities to people in the developing world?” The answer was: “Yes”.

We developed a high-quality generic medicine. Not only is it heat-stable (like its brand name counterpart), but it’s also approved by the World Health Organization as part of a second-line treatment option for people who have developed a resistance to first-line HIV/AIDS treatment. Today, the medicine is available in sub-Saharan Africa, Latin and Central America, the Caribbean and Southeast Asia.
Our efforts allowed us to increase access to this high-quality medicine and at the same time fulfil a commitment we made to former President Bill Clinton to lower the price of second-line treatment for HIV/AIDS in developing countries.




Last Updated:  20/03/2017